Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Sponsor
West China Hospital
Study ID
NCT06713057
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Locally Advanced Thyroid Gland Carcinoma
  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cyclophosphamide+Pemetrexed+5-Fluorouracil — DRUG
    IV or PO
  • Cyclophosphamide+Doxorubicin+5-Fluorouracil — DRUG
    IV or PO
  • Vindesine + Cisplatin — DRUG
    IV or PO
  • Doxorubicin + Cisplatin — DRUG
    IV or PO
  • Doxorubicin + Cyclophosphamide + Cisplatin — DRUG
    IV or PO
  • Docetaxel + Doxorubicin — DRUG
    IV or PO
  • Paclitaxel + Carboplatin — DRUG
    IV or PO
  • Paclitaxel + Doxorubicin — DRUG
    IV or PO
  • Paclitaxel + Cisplatin — DRUG
    IV or PO
  • Gemcitabine alone — DRUG
    IV or PO

Study Details

The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Key Dates

First listed
Dec 3, 2024
Start date
Dec 1, 2024
Status verified
Dec 2024
Primary completion
Dec 1, 2025
Completion
Jul 1, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Organoid-guided chemotherapeutic group
    Patients who take the recommended chemothetapy drugs regularly based on sensitivity analysis.

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: Every 2 months until 12 months ]

Central Contacts

Related Studies